Patient name/age: Bet, 43
Occupation: Stay-at-home parent
sUA >6 mg/dL
2/year
visible tophi
G6PD deficiency is a genetic disorder that causes red blood cells to break down prematurely or in response to certain medications, including KRYSTEXXA. It is the most common enzyme deficiency disorder of red blood cells worldwide.3,4
G6PD deficiency is the most common enzyme deficiency disorder of red blood cells, affecting 400 million people worldwide. G6PD predominantly affects males, particularly those of African, Mediterranean, or South Asian ancestry.4,5
Unlike the serum uric acid (sUA) test, which should be performed prior to each infusion, the G6PD deficiency screening should be conducted 1 time, prior to the first infusion.1*
Perform a standard blood draw for lab analysis. Either a qualitative or quantitative screening can be ordered to determine G6PD deficiency.5
*Because the test results are typically returned within 2 to 3 days, G6PD deficiency screening is recommended at the time the service request form is submitted or as early as possible.
G6PD, glucose-6-phosphate dehydrogenase.
SCREENING CLASSIFICATION | INTERPRETATION | RECOMMENDATION1 |
---|---|---|
Normal quantitative value OR negative qualitative result for deficiency. | Patient does not have G6PD deficiency. | Can proceed with treatment of KRYSTEXXA as indicated. |
Low quantitative value OR positive qualitative result for deficiency. | Patient may have G6PD deficiency.† | Do not administer KRYSTEXXA to patients with G6PD deficiency. If you have general questions regarding screening for G6PD deficiency, please call Medical Information at 866-479-6742. |
SCREENING CLASSIFICATION | Normal quantitative value OR negative qualitative result for deficiency. | Low quantitative value OR positive qualitative result for deficiency. |
INTERPRETATION | Patient does not have G6PD deficiency. | Patient may have G6PD deficiency.† |
RECOMMENDATION1 | Can proceed with treatment of KRYSTEXXA as indicated. |
Do not administer KRYSTEXXA to patients with G6PD deficiency. If you have general questions regarding screening for G6PD deficiency, please call Medical Information at 866-479-6742. |
KRYSTEXXA is contraindicated for patients with a history of serious hypersensitivity reactions, including anaphylaxis, to KRYSTEXXA or any of its components.
†Acute hemolytic anemia, which may be the result of the patient’s medications, can produce inaccurate results. Additionally, if a patient has received a blood transfusion in the past 90 days, the transfusion could alter the test results. For either of these situations, postpone testing or consider retesting in 2 to 3 months.2,4
Connect with the KRYSTEXXA team to discuss.
Horizon By Your Side provides patients with personalized non-medical support once they are prescribed KRYSTEXXA.
sUA >6 mg/dL
2/year
visible tophi
Gout Flares: An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including KRYSTEXXA. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.
Congestive Heart Failure: KRYSTEXXA has not been formally studied in patients with congestive heart failure, but some patients in the pre-marketing placebo-controlled clinical trials experienced exacerbation. Exercise caution in patients who have congestive heart failure and monitor patients closely following infusion.
The most commonly reported adverse reactions (≥5%) are:
KRYSTEXXA co-administration with methotrexate trial:
KRYSTEXXA with methotrexate: gout flares, arthralgia, COVID-19, nausea, and fatigue; KRYSTEXXA alone: gout flares, arthralgia, COVID-19, nausea, fatigue, infusion reaction, pain in extremity, hypertension, and vomiting.
KRYSTEXXA pre-marketing placebo-controlled trials:
gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis, and vomiting.
KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.
Please see Full Prescribing Information, including Boxed Warning.
Gout Flares: An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including KRYSTEXXA. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.
Congestive Heart Failure: KRYSTEXXA has not been formally studied in patients with congestive heart failure, but some patients in the pre-marketing placebo-controlled clinical trials experienced exacerbation. Exercise caution in patients who have congestive heart failure and monitor patients closely following infusion.
The most commonly reported adverse reactions (≥5%) are:
KRYSTEXXA co-administration with methotrexate trial:
KRYSTEXXA with methotrexate: gout flares, arthralgia, COVID-19, nausea, and fatigue; KRYSTEXXA alone: gout flares, arthralgia, COVID-19, nausea, fatigue, infusion reaction, pain in extremity, hypertension, and vomiting.
KRYSTEXXA pre-marketing placebo-controlled trials:
gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis, and vomiting.
KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.
Please see Full Prescribing Information, including Boxed Warning.